CVS Health's DEI Employment Practices: What the Company's Own Documents Show — and What They Mean for Employees

Published August 27, 2026 · Last updated August 27, 2026 · By Fett Law — Michigan Employment Discrimination Attorneys

Between 2021 and 2023, CVS Health Corporation told its own investors that it reduced executive bonuses when the company fell short on racial, ethnic and gender representation — a "Workforce Diversity Modifier" that by 2023 reached every colleague at Vice President and above. CVS Health also ran a leadership program open to "multicultural female colleagues," funded a $5 million scholarship limited to "Black and Latinx students," and set out to raise the share of its apprentices who "self-identify as Black or African American." Roughly 20% of CVS Health's total revenue comes from the federal government. Similar practices were the basis of IBM's $17,077,043 False Claims Act settlement with the U.S. Department of Justice in April 2026 and Deloitte's $21.5 million settlement in August 2026.

Key facts

Did CVS Health tie executive pay to diversity targets?

CVS Health defined the mechanism itself, in its proxy statement filed with the Securities and Exchange Commission on April 1, 2022:

"In addition to our core metrics, a Workforce Diversity Modifier may be applied for senior leadership (SVP and above, including our NEOs) based on CVS Health's progress in achieving a greater diverse leadership representation during the year. This modifier ranges from minus 10% to zero (no change) and will be applied to the final recommended bonuses, after Company performance and individual modifiers have been determined, to ensure consistency of approach." CVS Health Corporation, 2022 Proxy Statement (Schedule 14A), filed April 1, 2022, p. 52 (Compensation Discussion and Analysis)

The company described the same arrangement to the public in its own ESG reporting:

"For senior vice presidents and above, during 2021 we began tying compensation to performance in advancing racial, ethnic and gender representation and will expand this to vice presidents and above in 2023" CVS Health, 2022 ESG Report, p. 16 ("Workforce representation")

And in its 2021 diversity report, CVS Health described the principle behind it as "holding leaders accountable for results, including tying a portion of their compensation to demonstrated progress."

What this meant in practice

Two features of the CVS Health design matter, and it is worth being precise about both.

It was downward-only. The modifier ran from minus 10% to zero. A CVS Health leader could not earn extra money by improving demographic numbers; the leader could only lose money by failing to improve them. That is a penalty structure, and for an executive facing it, the incentive it creates is the same one a bonus would create — the composition of the people that leader hired and promoted became a term of that leader's own pay.

It reached deep into management. In its 2023 proxy statement, CVS Health told stockholders it was "[e]xpanding the group of colleagues subject to the Workforce Diversity Modifier (downward only) to Vice Presidents and above, and providing greater transparency on the MP&D Committee's assessment of this metric within the CD&A." The 2024 proxy confirmed the expansion took effect: "For 2023, the MIP design expanded the group of colleagues subject to the Workforce Modifier to Vice Presidents and above, as the MP&D Committee believes that our workforce should reflect the customers and communities we serve." CVS Health's own 2023 appendix reported that "[i]n 2023, colleagues at Vice President and above had a downward-only modifier reflecting this goal." CVS Health disclosed 475 colleagues at the Vice President level and above in 2023.

CVS Health disclosed one assessment outcome. For 2021, the compensation committee "evaluated the Company's progress toward workforce diversity in 2021 and based on that evaluation did not apply an adjustment." We did not locate a disclosed assessment result for fiscal 2022, 2023 or 2024. Whether the modifier was ever actually applied to reduce a payout is not established by the public record.

Source status: the proxy statements remain available through the SEC's EDGAR system and CVS Health's investor site. The 2022 ESG Report and the 2023 impact report appendix remain live on cvshealth.com; the full 2021 ESG Report PDF now returns a 404 error, and the company's report-archive page has been removed.

Did CVS Health run programs restricted by race or sex?

Strategies for Success – Multicultural Women

CVS Health's 2021 Strategic Diversity Management Report describes a leadership program defined by two protected traits at once:

"Our Strategies for Success Multicultural Women, a customized leadership program, has graduated more than 300 high-potential multicultural female colleagues at CVS Health." CVS Health, 2021 Strategic Diversity Management Report ("2021 Diversity Highlights"), p. 4

The prior year's report described the same program as one where "more than 260 colleagues have completed the program, which seeks to equip participants with the tools they need to take their careers to the next level of leadership." That is the operative point for an employee. A program that exists to move people to "the next level of leadership" is a career accelerator. If access to it turned on being both non-white and female, then the colleagues who were not both — white women, men of any race — were outside a development track their employer was running for the same jobs they wanted.

The CVS Health Foundation Health Care Careers Scholarship

On January 28, 2021, the CVS Health Foundation announced a five-year, $5 million scholarship program with UNCF. The eligibility language was explicit:

"Black and Latinx students attending an accredited four-year college or university in the United States with an interest in pursuing a career in the health care sector are eligible to apply for the need-based awards." CVS Health Foundation announcement, January 28, 2021 — the CVS Health page has been deleted; text preserved on UNCF's site

CVS Health's then-Senior Vice President and Chief Diversity Officer described the purpose in the same announcement: "This scholarship will feed a robust pipeline of under-represented students, which will in turn strengthen the pool of talented college graduates ready for today's and tomorrow's workplace." CVS Health's 2020 Strategic Diversity Management Report likewise recorded a "five-year, $5 million CVS Health Foundation Health Care Careers Scholarship program for Black and Latinx students pursuing a career in health care."

One point requires care before anyone relies on it: a separate CVS Health wire release dated March 31, 2021 describes the same $5 million UNCF program as being for "Black and Latinx colleagues" rather than students. If that wording is accurate, the program reached CVS Health's own employees, which would change its character materially. We flag the discrepancy rather than resolve it — anyone who applied to, was admitted to, or was turned away from this program has direct knowledge that the public record does not.

Source status: the original CVS Health announcement page at cvshealth.com/news/community/cvs-health-foundation-establishes-5-million-college-scholarship.html now redirects to a generic news hub. The text is preserved on UNCF's website and in the 2020 report PDF, which remains live.

Did CVS Health target hiring by race?

The apprenticeship language is the company's own:

"Welcomed more than 8,000 registered apprentices to CVS Health, with a focus on increasing the representation of registered apprentices who self-identify as Black or African American. In 2021, 27% of registered apprentices identified as Black or African American and 46% identified as people of color." CVS Health, 2021 Strategic Diversity Management Report, p. 7 ("Workforce initiatives")

Read plainly, that sentence describes an entry point into employment at CVS Health where the company set out to change the racial composition of who came through it. Whether it did so by where it recruited, how it screened, or whom it selected is not disclosed — and that distinction is exactly what determines the legal analysis. Recruiting broadly is lawful; making the selection itself turn on race is not.

The same report recorded that CVS Health "[e]xpanded recruitment efforts from 11 to 87 historically Black colleges and universities and from 44 to 90 Hispanic-serving institutions," and reported a "200% increase in the hiring and promotion of Black and Hispanic colleagues to executive positions since 2019."

What we did not find matters too. Several large employers published mandates requiring that candidate slates include members of specified racial groups. We searched CVS Health's SEC filings, diversity reports and careers materials and located no such requirement. The only use of the phrase "diverse slate" in any CVS Health SEC filing appears in the 2021 proxy statement and concerns the board's CEO succession process, not employee hiring. We say so plainly because the difference matters: on the public record, CVS Health's documented conduct centers on pay tied to representation and trait-restricted programs, not on slate mandates.

Why is Texas investigating CVS Health's diversity program?

The letter, from the Chief of Healthcare Program Enforcement and an Assistant Attorney General, was addressed to CVS Health's Executive Vice President and General Counsel. It alleges that CVS Health touts its supplier diversity program as "one of the most active and progressive supplier diversity" efforts among corporations, and that the program directs hundreds of millions of dollars in purchasing to businesses owned by members of preferred groups — described in the letter as "Minority-and-Women-Owned Enterprises" and "Lesbian, Gay, Bisexual, and/or Transgender Business Enterprises" — giving them access to contracts that non-preferred suppliers cannot obtain as readily.

The statutes the letter invokes are the same ones that govern employment: Title VII of the Civil Rights Act of 1964 (42 U.S.C. § 2000e-2), 42 U.S.C. § 1981, Title VI, Section 1557 of the Affordable Care Act, Chapter 21 of the Texas Labor Code, and the Texas Health Care Program Fraud Prevention Act. The letter also invokes Executive Order 14173, the January 2025 order restricting DEI programs at federal contractors. Attorney General Ken Paxton, in the accompanying May 12, 2026 press release: "People must be judged on the basis of merit, not the color of their skin. My office will stand firmly against racist DEI policies."

CVS Health was given 14 days to respond. As of this writing we have located no public response and no filed enforcement action.

Why an employee should care about a supplier program. The Texas letter is about contracting, not hiring. But the theory it advances — that operating trait-based preferences while billing government health care programs creates fraud exposure — is the same theory the U.S. Department of Justice used against IBM and Deloitte, and there it was applied to employment practices. A state attorney general has now put CVS Health on written notice of that theory.

How CVS Health's DEI program changed, 2019–2026

The deletions are worth stating plainly, because they are the part of this record most likely to be missed. A program that no longer appears on a company website was not necessarily lawful while it ran, and it was not necessarily brief. CVS Health published detailed workforce race and gender tables through its 2023 appendix and then stopped. The documents quoted on this page were public statements by the company at the time it made them.

Why these practices matter legally

Title VII protects everyone. 42 U.S.C. § 2000e-2 makes it unlawful to discriminate against any individual because of race, color, religion, sex or national origin. It has no majority-group exception. Two recent Supreme Court decisions have made these claims easier to bring. In Muldrow v. City of St. Louis (2024), the Court held that a Title VII plaintiff challenging a transfer need show only some harm to a term or condition of employment, not "significant" harm. In Ames v. Ohio Department of Youth Services (2025), a unanimous Court rejected the "background circumstances" rule that some courts of appeals had used to require majority-group plaintiffs to make an extra showing.

Section 1981 reaches race discrimination in employment, with no damages cap. 42 U.S.C. § 1981 guarantees the same right to make and enforce contracts regardless of race. It requires no charge with the Equal Employment Opportunity Commission first and carries a four-year limitations period.

For federal contractors, there is a False Claims Act dimension. Executive Order 14173, signed January 21, 2025, requires federal contracts to include terms under which the contractor agrees that "compliance in all respects with all applicable Federal anti-discrimination laws is material to the government's payment decisions" for purposes of 31 U.S.C. § 3729(b)(4), and certifies that it does not operate DEI programs that violate those laws.

The False Claims Act route for federal contractors. On April 10, 2026, the U.S. Department of Justice announced that IBM would pay $17,077,043 to resolve False Claims Act allegations that it failed to comply with anti-discrimination requirements in its federal contracts — the first settlement under the DOJ's Civil Rights Fraud Initiative. In August 2026 the government resolved a second, larger matter: under a settlement agreement effective August 21, 2026, five Deloitte entities agreed to pay $21,500,000, of which $9,995,000 was restitution, covering conduct from January 1, 2017 through the settlement date. The certification hook is specific — Title VII as incorporated into federal contracts and FAR clause 52.222-26 — and the government's theory reached not only what Deloitte certified to its contracting agencies but what it "publicly represented" about its compliance. The agreement adds a second and independent theory: that Deloitte "allocated costs to its federal government contracts relating to these practices and sought payment and reimbursement under its federal government contracts for such costs." The whistleblower was paid $4,300,000. Both settlements resolved allegations only, with no determination of liability, and Deloitte denies the conduct.

Where CVS Health sits. CVS Health's own Form 10-K states that federal government revenue was "approximately 20% of the Company's consolidated total revenues in 2025, 2024 and 2023," with CMS Medicare contracts accounting for about 79% of that federal revenue in 2025. Aetna Life Insurance Company underwrites Federal Employees Health Benefits plans under contract CS 2900 with the U.S. Office of Personnel Management, and the Federal Employees Health Benefits Acquisition Regulation incorporates the standard federal Equal Opportunity clause (FAR 52.222-26) into carrier contracts. CVS Pharmacy, Inc. separately held a $185,307,164 prime contract with the Centers for Disease Control and Prevention running from June 2022 to May 2025. That is the parallel fact to IBM and Deloitte. Whether it produces the same legal consequence for CVS Health has not been tested — no enforcement action against CVS Health on this theory has been filed.

For the full framework — the four practice categories courts and the Justice Department have focused on, and when an employee can sue — see our guide, Is DEI Illegal? 4 Illegal DEI Practices & When You Can Sue.

Were you affected by these practices at CVS Health?

These are the situations the documents on this page describe. You do not need to be certain any of them applied to you.

• You were passed over for a promotion by a Vice President or above between 2021 and 2023. During those years, the person making that decision was working under a bonus modifier tied to the company's progress on racial, ethnic and gender representation. That is not proof of anything about your case — but it is a documented feature of the decision-making environment, disclosed by CVS Health itself.
• You were not eligible for a leadership development program because of your race or sex. Strategies for Success – Multicultural Women graduated more than 300 colleagues. If you sought that kind of development track and were outside its criteria, you were competing against colleagues who received training you could not access.
• You applied for the CVS Health Foundation Health Care Careers Scholarship, or were told you could not. Its published eligibility was limited to Black and Latinx applicants.
• You were a CVS Health manager whose own compensation depended on demographic outcomes. If you were at Vice President level or above in 2023, CVS Health's own appendix says you were. Managers in that position sometimes have the clearest view of how the metric actually changed decisions — and are sometimes the ones who suffered for refusing to let it.
• You have first-hand knowledge of how the Workforce Diversity Modifier was calculated or applied. The mechanics — which demographic categories were measured, what thresholds applied, how business-unit results rolled up — were never disclosed publicly. People inside CVS Health know them.
• You were involved in the registered apprenticeship program or in campus recruiting and saw how the stated focus on Black and African American representation was implemented in actual selection decisions.

A federal settlement is not a substitute for your own claim: when the Justice Department resolved the Deloitte matter, it expressly preserved the EEOC's right to pursue charges alleging the very same conduct, and preserved individual liability. Nothing about that settlement compensated a single employee or applicant.

Talking to a lawyer costs nothing and commits you to nothing. If you would like to know who you would be talking to first, meet our DEI discrimination lawyers.

If you have insider knowledge and CVS Health's federal business is involved: the False Claims Act allows a private individual to sue on the government's behalf and to share in any recovery. Those complaints are filed under seal, so the employer is not told while the government investigates. Both the False Claims Act (31 U.S.C. § 3730(h)) and Title VII (42 U.S.C. § 2000e-3(a)) prohibit retaliation against people who report or oppose unlawful practices.

What could a claim against CVS Health be worth?

Whistleblower recoveries under the False Claims Act

Under 31 U.S.C. § 3730(d), a qui tam relator receives 15–25% of the government's recovery when the Department of Justice intervenes, and 25–30% when the relator proceeds without intervention. The Deloitte settlement supplies a paid benchmark rather than a projection: the relator received $4,300,000 — exactly 20% of a $21,500,000 recovery. That settlement also shows why False Claims Act exposure outruns the money actually lost. Of the $21.5 million, $9,995,000 was restitution — roughly the government's single damages — so the resolution came to about 2.15 times the actual loss, because FCA recoveries are built on multiplied damages plus per-claim penalties. As a second illustration, arithmetic alone: an intervened case resolving at IBM's $17,077,043 would pay a relator roughly $2.6–$4.3 million. A contractor with a larger federal book or a longer conduct period could produce a materially larger number.

Damages in an individual discrimination case

Back pay and front pay are uncapped under Title VII. Compensatory and punitive damages are capped by employer size — $50,000 for employers with 15–100 employees, $100,000 for 101–200, $200,000 for 201–500, and $300,000 for employers with more than 500. CVS Health, with over 300,000 colleagues, sits at the $300,000 cap. That cap is why race claims are often brought under 42 U.S.C. § 1981 instead, which has no damages cap at all. Many state statutes are also uncapped — Michigan's Elliott-Larsen Civil Rights Act among them. Prevailing plaintiffs generally recover attorney's fees on top of damages.

For scale, from this firm's own prior results: a $10.5 million race and age discrimination class action against Ford Motor Company, a $1.1 million jury judgment against the Michigan State Police, and a $460,000 reverse-discrimination settlement for three corrections officers. Prior results do not guarantee a similar outcome.

Class action potential

Class actions are built on a single policy applied to many people. A compensation modifier that applied to every colleague at Vice President and above, or a development program with uniform eligibility criteria, is that kind of common policy. Historic employment-discrimination class recoveries show the scale such cases can reach — Coca-Cola settled for $192.5 million in 2000, Texaco for $176.1 million in 1996, and Novartis for $175 million in 2010. We are not aware of any pending class action against CVS Health on these facts.

Every case depends on its own facts. These figures show the range the law makes possible, not a prediction. The way to find out where you actually stand is to start a confidential intake.

Sources